CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to http://www.clinuvel.com. SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD
View Top Employees from CLINUVEL PHARMACEUTICALS LTDWebsite | http://www.clinuvel.com |
Ticker | CUV |
Revenue | $20 million |
Employees | 75 (65 on RocketReach) |
Founded | 2001 |
Address | Level 22, 535 Bourke Street, Melbourne, Victoria 3000, AU |
Phone | +61 3 9660 4900 |
Fax | +61 3 9660 4909 |
Technologies |
JavaScript,
HTML,
PHP
+30 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Drug development, Healthcare, Science and Engineering, Drug commercialisation, Developer Platform, Photomedicine, Software, Pharmaceutical, Health Care |
Web Rank | 2 Million |
Keywords | Clinuvel Pharmaceuticals, The Math Of Upf Rating Scale, 沙拉 健康, Clinuvel Pharmaceut, Photosensitive Disorder Photodynamic Therapy |
Competitors | Active Biotech AB, Corcept Therapeutics, Lipocine Inc., MediQuest Therapeutics, Inc., Yaupon Therapeutics, Inc |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 621 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 62151 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 6215 Companies, NAICS Code 62 Companies |
Looking for a particular CLINUVEL PHARMACEUTICALS LTD employee's phone or email?
The CLINUVEL PHARMACEUTICALS LTD annual revenue was $20 million in 2024.
Daniela S is the Vice President Public Relations of CLINUVEL PHARMACEUTICALS LTD.
65 people are employed at CLINUVEL PHARMACEUTICALS LTD.
CLINUVEL PHARMACEUTICALS LTD is based in Melbourne, Victoria.
The NAICS codes for CLINUVEL PHARMACEUTICALS LTD are [621, 32541, 3254, 62151, 325, 32, 6215, 62].
The SIC codes for CLINUVEL PHARMACEUTICALS LTD are [283, 28].